Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

Rhea-AI Summary

Rain Oncology Inc. (RAIN) has announced that its abstract on milademetan, an oral MDM2-p53 inhibitor, will be presented at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland. The presentation, titled "MDM2 inhibitor milademetan: safety profile and management of adverse events (AEs)", will take place on March 21, 2023, at 10:50 AM CET. This event underscores the company's commitment to developing precision oncology therapies that target oncogenic drivers. Milademetan aims to reactivate p53, and further materials from the presentation will be available on the Rain website after the event.

Positive

• Abstract on milademetan accepted for proffered presentation at a prestigious conference.
• Focus on safety profile and management of adverse events may enhance understanding of milademetan's therapeutic potential.

Negative

• None.

NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland.

Presentation Title:	MDM2 inhibitor milademetan: safety profile and management of adverse events (AEs)
Presentation Number:	43O
Presenter:	Chiara Fabbroni, MD, National Cancer Institute, Milan, Italy
Session Date and Time:	Tuesday, March 21, 2023, 10:50am-12:10pm Central European Time
Location:	Hall A

A copy of the presentation materials can be accessed by visiting the “Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of the MDM2-p53 complex that reactivates p53.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com        

FAQ

What is Rain Oncology Inc. presenting at the ESMO Congress?

Rain Oncology Inc. is presenting its abstract titled 'MDM2 inhibitor milademetan: safety profile and management of adverse events (AEs)' at the ESMO Sarcoma and Rare Cancers Annual Congress in Lugano on March 21, 2023.

When is Rain's presentation scheduled at the ESMO Congress?

The presentation by Rain Oncology Inc. is scheduled for March 21, 2023, from 10:50 AM to 12:10 PM Central European Time.

What is milademetan and its significance in precision oncology?

Milademetan is an oral MDM2-p53 inhibitor developed by Rain Oncology Inc. that aims to reactivate p53, targeting oncogenic drivers in cancer treatment.

Where can I find the presentation materials for Rain's ESMO Congress presentation?

The presentation materials will be available in the 'Resources' section of the Rain website after the presentation concludes.